Ind-Swift Laboratories Ltd. Share Price & Stock Analysis

Ind-Swift Laboratories Ltd. (NSE: INDSWFTLAB, BSE: 532305) is a Manimajra, Chandigarh-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹3,158 Cr, it ranks #1,034 by market cap among the 6,197 Indian listed companies on FinBizNet, and #33 of 86 in Medicinal Chemicals and Botanical Products. At ₹363.95 (as of 16 Nov 2026), the share price is 14.7% below its 52-week high of ₹426.60 and 312.9% above its 52-week low of ₹88.15. The share price is up 257.4% over one year and up 21.8% over three months.

Key Metrics

Current Price₹363.95
Market Cap₹3,158 Cr
NSE SymbolINDSWFTLAB
BSE Code532305
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E Ratio71.4
Return on Equity3.24%
Return on Assets0.66%
52-Week Range₹88.15 – ₹426.60
1-Year Price Change+257.4%
3-Month Price Change+21.8%
Beta (1Y)0.78
Dividend Yield0.00%
HeadquartersManimajra, Chandigarh
Websitewww.indswiftlabs.com

Latest Quarterly Results — Q2 FY27

Revenue₹240 Cr
Net Profit₹34 Cr
Net Margin14.2%
EPS (Basic)₹3.94
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Ind-Swift Laboratories Ltd. Quarterly Revenue and Profit Trend

Ind-Swift Laboratories Ltd. reported revenue of ₹240 Cr in Q2 FY27, up 57.5% from ₹153 Cr in Q2 FY26 and up 25.6% from ₹191 Cr in Q1 FY27. It posted a net profit of ₹34 Cr for the quarter, against a net profit of ₹8 Cr in Q2 FY26 (up 328.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹138 Cr (Q4 FY25) to ₹240 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹240 Cr₹34 Cr14.2%
Q1 FY27₹191 Cr₹25 Cr12.9%
Q4 FY26₹170 Cr₹15 Cr8.9%
Q3 FY26₹151 Cr₹10 Cr6.3%
Q2 FY26₹153 Cr₹8 Cr5.2%
Q1 FY26₹153 Cr₹9 Cr5.7%
Q4 FY25₹138 Cr₹222 Cr160.8%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 42.93% of Ind-Swift Laboratories Ltd.'s shares as of Sept 2026, against 39.50% in Dec 2025 (+3.43 percentage points). Delivery averaged 44.5% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Ind-Swift Laboratories Ltd.

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson’s disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride,

Products and Services

1. Pharmaceutical Business-This segment develops, manufactures, and sells active pharmaceutical ingredients.

Business Segments

1. Pharmaceutical Business-100%

Ind-Swift Laboratories Ltd. vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Ind-Swift Laboratories Ltd.₹3,158 Cr71.43.24%₹240 Cr+257.4%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Ind-Swift Laboratories Ltd.?

Ind-Swift Laboratories Ltd. is trading at ₹363.95, with a market capitalisation of ₹3,158 Cr.

Which sector does Ind-Swift Laboratories Ltd. belong to?

Ind-Swift Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Ind-Swift Laboratories Ltd.?

Ind-Swift Laboratories Ltd. has a P/E of 71.4 and a return on equity of 3.24%.

What is the stock symbol of Ind-Swift Laboratories Ltd.?

Ind-Swift Laboratories Ltd. is listed on the NSE under the symbol INDSWFTLAB and on the BSE under the scrip code 532305.

How has Ind-Swift Laboratories Ltd.'s share price moved over the past year?

Ind-Swift Laboratories Ltd.'s share price is up 257.4% over one year and up 21.8% over three months. Its 52-week range is ₹88.15 to ₹426.60.

What were Ind-Swift Laboratories Ltd.'s latest quarterly results?

In Q2 FY27, Ind-Swift Laboratories Ltd. reported revenue of ₹240 Cr and net profit of ₹34 Cr, with basic EPS of ₹3.94 (consolidated, parsed from the company's exchange filing).

How have Ind-Swift Laboratories Ltd.'s revenue and profit changed over the past year?

Ind-Swift Laboratories Ltd. reported revenue of ₹240 Cr in Q2 FY27, up 57.5% from ₹153 Cr in Q2 FY26 and up 25.6% from ₹191 Cr in Q1 FY27.

What is the promoter holding in Ind-Swift Laboratories Ltd.?

Promoters held 42.93% of Ind-Swift Laboratories Ltd.'s shares as of Sept 2026, against 39.50% in Dec 2025 (+3.43 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.